GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (NAS:VXRT) » Definitions » Total Assets

Vaxart (Vaxart) Total Assets : $91.83 Mil (As of Dec. 2023)


View and export this data going back to 1990. Start your Free Trial

What is Vaxart Total Assets?

Vaxart's Total Assets for the quarter that ended in Dec. 2023 was $91.83 Mil.

During the past 12 months, Vaxart's average Total Assets Growth Rate was -10.30% per year. During the past 3 years, the average Total Assets Growth Rate was 26.60% per year. During the past 5 years, the average Total Assets Growth Rate was 23.50% per year. During the past 10 years, the average Total Assets Growth Rate was 16.50% per year.

During the past 13 years, Vaxart's highest 3-Year average Total Assets Growth Rate was 157.80%. The lowest was -64.10%. And the median was 15.50%.

Total Assets is connected with ROA %. Vaxart's annualized ROA % for the quarter that ended in Dec. 2023 was -70.39%. Total Assets is also linked to Revenue through Asset Turnover. Vaxart's Asset Turnover for the quarter that ended in Dec. 2023 was 0.07.


Vaxart Total Assets Historical Data

The historical data trend for Vaxart's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxart Total Assets Chart

Vaxart Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.03 152.58 221.17 153.85 91.83

Vaxart Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 153.85 129.85 122.65 105.64 91.83

Vaxart Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Vaxart's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=57.805+34.025
=91.83

Vaxart's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (Q: Dec. 2023 )+Total Liabilities (Q: Dec. 2023 )
=57.805+34.025
=91.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vaxart  (NAS:VXRT) Total Assets Explanation

Total Assets is connected with ROA %.

Vaxart's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-69.5/( (105.642+91.83)/ 2 )
=-69.5/98.736
=-70.39 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Vaxart's Asset Turnover for the quarter that ended in Dec. 2023 is

Asset Turnover
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=6.625/( (105.642+91.83)/ 2 )
=6.625/98.736
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Vaxart Total Assets Related Terms

Thank you for viewing the detailed overview of Vaxart's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxart (Vaxart) Business Description

Traded in Other Exchanges
Address
170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
Executives
W. Mark Watson director 324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Phillip E Lee officer: Chief Financial Officer C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Elaine J Heron director 6 STONEGATE RD, PONTOLA VALLEY CA 94028
Fuad Ahmad officer: Interim CFO 461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Edward B Berg officer: SVP, General Counsel C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Robert A. Yedid director C/O LIFESCI ADVISORS, 250 WEST 55TH STREET, SUITE 3401, NEW YORK NY 10019
Margaret Echerd officer: VP, Corporate Controller, PAO 3585 MONROE STREET, SANTA CLARA CA 95051
James F. Cummings officer: Chief Medical Officer 1312 BEACHVIEW ROAD, ANNAPOLIS MD 21403
Julie M Cherrington director 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Sean Tucker officer: Chief Scientific Officer 385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
Wouter Latour director, officer: President and Chief Executive 385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
David E. Wheadon director C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Karen J Wilson director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037

Vaxart (Vaxart) Headlines